Consider Muscle Disease in Children with Elevated Transaminase

References

1. 1.↵
   1. Pearson CM,
   2. Chowdhury SR,
   3. Fowler WM Jr.,
   4. Jones MH,
   5. Griffith WH

   . Studies of enzymes in serum in muscular dystrophy. II. Diagnostic and prognostic significance in relatives of dystrophic persons. Pediatrics 1961;28:962–70.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Somer H,
   2. Donner M,
   3. Murros J,
   4. Konttinen A

   . A serum isozyme study in muscular dystrophy. Particular reference to creatine kinase, aspartate aminotransferase, and lactic acid dehydrogenase isozymes. Arch Neurol 1973;29:343–5.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   1. Thomson WH

   . Serum enzyme studies in inherited disease of skeletal muscle. Clin Chim Acta 1971;35:183–91.

   OpenUrlPubMed
4. 4.↵
   1. Munsat TL,
   2. Baloh R,
   3. Pearson CM,
   4. Fowler W Jr.

   . Serum enzyme alterations in neuromuscular disorders. JAMA 1973;226:1536–43.

   OpenUrlCrossRefPubMedWeb of Science
5. 5.↵
   1. Sibley JA,
   2. Lehninger AL

   . Aldolase in the serum and tissue of tumor-bearing animals. J Natl Cancer Inst 1949;9:303–9.

   OpenUrlFREE Full Text
6. 6.↵
   1. Thomson WH

   . Serum enzyme studies in acquired disease of skeletal muscle. Clin Chim Acta 1971;35:193–9.

   OpenUrlPubMed
7. 7.↵
   1. Wroblewski F

   . The clinical significance of transaminase activities of serum. Am J Med 1959;27:911–23.

   OpenUrlCrossRefPubMedWeb of Science
8. 8.↵
   1. Wroblewski F,
   2. Ladue JS

   . Serum glutamic pyruvic transaminase in cardiac with hepatic disease. Proc Soc Exp Biol Med 1956;91:569–71.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Rosales XQ,
   2. Chu ML,
   3. Shilling C,
   4. Wall C,
   5. Pastores GM,
   6. Mendell JR

   . Fidelity of gamma-glutamyl transferase (GGT) in differentiating skeletal muscle from liver damage. J Child Neurol 2008;23:748–51.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Urganci N,
    2. Arapoglu M,
    3. Serdaroglu P,
    4. Nuhoglu A

    . Incidental raised transaminases: a clue to muscle disease. Ann Trop Paediatr 2006;26:345–8.

    OpenUrlCrossRefPubMedWeb of Science
11. 11.↵
    1. Zamora S,
    2. Adams C,
    3. Butzner JD,
    4. Machida H,
    5. Scott RB

    . Elevated aminotransferase activity as an indication of muscular dystrophy: case reports and review of the literature. Can J Gastroenterol 1996;10:389–93.

    OpenUrlPubMedWeb of Science
12. 12.↵
    1. Rutledge J,
    2. Andersen J,
    3. Fink CW,
    4. Cook J,
    5. Strickland A

    . Persistent hypertransaminasemia as the presenting finding of childhood muscle disease. Clin Pediatr (Phila) 1985;24:500–3.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Emery AE

    . Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul Disord 1991;1:19–29.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Ciafaloni E,
    2. Fox DJ,
    3. Pandya S,
    4. et al

    . Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet). J Pediatr 2009;155:380–5.

    OpenUrlCrossRefPubMedWeb of Science
15. 15.↵
    1. Balaban B,
    2. Matthews DJ,
    3. Clayton GH,
    4. Carry T

    . Corticosteroid treatment and functional improvement in Duchenne muscular dystrophy: long-term effect. Am J Phys Med Rehabil 2005;84:843–50.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Bushby K,
    2. Finkel R,
    3. Birnkrant DJ,
    4. et al

    . Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 2010;9:77–93.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Merlini L,
    2. Cicognani A,
    3. Malaspina E,
    4. et al

    . Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003;27:222–7.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Moxley RT 3rd.,
    2. Ashwal S,
    3. Pandya S,
    4. et al

    . Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2005;64:13–20.

    OpenUrlAbstract/FREE Full Text
19. 19.↵
    1. Manzur AY,
    2. Kuntzer T,
    3. Pike M,
    4. Swan A

    . Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2008;(1):CD003725.
20. 20.↵
    1. Morse RP,
    2. Rosman NP

    . Diagnosis of occult muscular dystrophy: importance of the “chance” finding of elevated serum aminotransferase activities. J Pediatr 1993;122:254–6.

    OpenUrlPubMedWeb of Science
21. 21.↵
    1. van Deutekom JC,
    2. Janson AA,
    3. Ginjaar IB,
    4. et al

    . Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357:2677–86.

    OpenUrlCrossRefPubMedWeb of Science
22. 22.↵
    1. Kinali M,
    2. Arechavala-Gomeza V,
    3. Feng L,
    4. et al

    . Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009;8:918–28.

    OpenUrlCrossRefPubMedWeb of Science